- Home
- DMAC vs DMF Comparison
DMAC vs DMF Comparison
Compare DMAC & DMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- DMF
- Stock Information
- Founded
- DMAC 2000
- DMF 1988
- Country
- DMAC United States
- DMF United States
- Employees
- DMAC N/A
- DMF N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- DMF Finance/Investors Services
- Sector
- DMAC Health Care
- DMF Finance
- Exchange
- DMAC Nasdaq
- DMF Nasdaq
- Market Cap
- DMAC 158.1M
- DMF 152.2M
- IPO Year
- DMAC N/A
- DMF N/A
- Fundamental
- Price
- DMAC $4.11
- DMF $6.97
- Analyst Decision
- DMAC Strong Buy
- DMF
- Analyst Count
- DMAC 2
- DMF 0
- Target Price
- DMAC $8.00
- DMF N/A
- AVG Volume (30 Days)
- DMAC 102.4K
- DMF 60.7K
- Earning Date
- DMAC 05-13-2025
- DMF 01-01-0001
- Dividend Yield
- DMAC N/A
- DMF 2.66%
- EPS Growth
- DMAC N/A
- DMF N/A
- EPS
- DMAC N/A
- DMF 0.15
- Revenue
- DMAC N/A
- DMF N/A
- Revenue This Year
- DMAC N/A
- DMF N/A
- Revenue Next Year
- DMAC N/A
- DMF N/A
- P/E Ratio
- DMAC N/A
- DMF $45.13
- Revenue Growth
- DMAC N/A
- DMF N/A
- 52 Week Low
- DMAC $2.14
- DMF $5.37
- 52 Week High
- DMAC $6.82
- DMF $6.79
- Technical
- Relative Strength Index (RSI)
- DMAC 50.90
- DMF 47.38
- Support Level
- DMAC $3.92
- DMF $6.84
- Resistance Level
- DMAC $4.33
- DMF $7.06
- Average True Range (ATR)
- DMAC 0.29
- DMF 0.06
- MACD
- DMAC 0.02
- DMF -0.00
- Stochastic Oscillator
- DMAC 56.79
- DMF 52.00
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.